论文部分内容阅读
乙型肝炎病毒在人体内持续复制是引起肝功能损伤和免疫功能紊乱的主要因素。因此清除乙肝病毒、中止病毒复制是治疗慢性乙肝的重要环节。本文对６０例慢乙肝患者联合应用阿昔洛韦、抗乙肝核糖核酸治疗，结果发现，治疗组与对照组ＨＢＶ复制阴转率比较差异显著，治疗组三项血清ＨＢＶ复制标志全部阴转者５例，而对照组无一例阴转。提示这两组药物联合应用对乙肝病毒具有明显的抑制作用。
Hepatitis B virus replication in the human body is caused by liver damage and immune dysfunction, the main factor. Therefore, the removal of hepatitis B virus, stop replication of the virus is an important part of the treatment of chronic hepatitis B. In this paper, 60 patients with chronic hepatitis B combined application of acyclovir, anti-hepatitis B ribonucleic acid treatment and found that treatment group and control group HBV replication negative conversion rate was significantly different, the treatment group three serum HBV replication markers all negative conversion 5 Cases, and no negative control group. Prompt combination of these two groups of drugs has a significant inhibitory effect on hepatitis B virus.